DIA
Drug Information Association Logo

The Current State of Quality Oversight (QO) in the Pharmaceutical Industry

| Online

« Back to Listing

Overview 

Continuing Education credit or Certificate Program units are not available for Archived Webinars


What is quality oversight (QO)? Definitions remain unclear as to what, exactly, quality oversight should entail and how optimal quality oversight programs can be effected. Regulatory authorities have suggested a risk-based approach, but even that is subject to different interpretations. For example, for some sponsors, oversight is focused entirely at the site level. While a start, such an approach does not adequately capture trial components such as vendor monitoring processes. Anything less than a truly holistic approach will provide sub-optimal oversight. This webinar will provide a definition of QO and delve deeper into the state of QO today.


Archived Webinar available through October 31, 2014

Who Should Attend 

Professionals involved in:

  • Pharmaceutical, academic and government professionals involved in quality oversight and regulatory inspections, including vendors and CROs

Learning Objectives 

At the conclusion of this webinar, participants should be able to:

  • Define quality oversight
  • Discuss the state of quality oversight in the current regulatory environment

Contact Information 

Questions on Archived Webinar
Jessica Culp
DIA North America
Phone +1.215.442.6132
Fax +1.215.442.6199
Jessica.Culp@diahome.org

Technical Requirements 

Click here for minimum system requirements.

Presenter(s) 

Previous Next

Agenda  

Day 1 Thursday, Oct 10, 2013

  • 7:00AM - 11:59PM

    The Current State of Quality Oversight (QO) in the Pharmaceutical Industry

    Speaker(s):

    • The Current State of Quality Oversight (QO) in the Pharmaceutical Industry
      John R. Wilson, PhD
      Senior Vice President
      Beaufort LLC, United States
    • Coleen M. Glessner
      Vice President, Clinical Trial Process and Quality
      Pfizer Inc, United States
    • Sarah Jane Constantine
      Senior Manager, Clinical Trial Oversight and Compliance
      Cubist Pharmaceuticals, United States

Registration Fees 

Other Fees

Government (Full Time) Individual
$125.00
Charitable Nonprofit/Academia Individual
$175.00
Group Site
$799.00
Group Plus
$995.00

Member

Member Individual
$250.00

Non-Member

NonMember Individual
$295.00
Group Discounts

  • Group site registration is a license for ONE internet login allowing multiple viewers from one location.
  • Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.


CANCELLATIONS
No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.

Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.

Register Online

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top